View source for Max Delbrück Center for Molecular Medicine in the Helmholtz Association

{{Infobox organization
| name                    = <!-- defaults to {{PAGENAME}}, if not provided -->
| full_name               =
| native_name             = Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
| native_name_lang        = <!-- required ISO 639-1 code of the above native language -->
| logo                    = MDC Logo V1 RGB blue.svg
| logo_size               =
| logo_alt                =
| logo_caption            =
| image                   = Berlin-Buch BB012 Max-Delbrück-Centrum für Molekulare Medizin Max-Delbrück-Haus.jpg
| image_size              =
| alt                     = <!-- see [[WP:ALT]] -->
| caption                 =
| map                     = <!-- map image -->
| map_size                = <!-- defaults to 250px -->
| map_alt                 =
| map_caption             =
| map2                    = <!-- 2nd map image, if required -->
| map2_size               =
| map2_alt                =
| map2_caption            =
| abbreviation            =
| nickname                =
| pronounce               =
| pronounce ref           =
| pronounce comment       =
| pronounce 2             =
| named_after             = [[Max Delbrück]]
| predecessor             =Zentralinstitut für Molekularbiologie,<br />Zentralinstitut für Krebsforschung,<br />Zentralinstitut für Herz-Kreislaufforschung
| merged                  = <!-- any other organization(s) which it was merged into -->
| successor               =
| formation               = {{start date and age|1992|01|01}}
| founder                 = <!-- or |founders = -->
| founding_location       = [[Berlin]]
| dissolved               = <!-- or |defunct = --><!-- use {{end date and age|YYYY|MM|DD}} -->
| merger                  = <!-- other organizations (if any) merged with, to constitute the new organization -->
| type                    = [[Research institute]]
| tax_id                  = <!-- or |vat_id = (for European organizations) -->
| registration_id         = <!-- for non-profits -->
| status                  = <!-- legal status or description (company, charity, foundation, etc.) -->
| purpose                 = <!-- or |focus = --><!-- humanitarian, activism, peacekeeping, etc. -->
| professional_title      = <!-- for professional associations -->
| headquarters            =
| location_city           = Berlin
| location_country        =
| location_city2          =
| location_country2       =
| addnl_location_city     =
| addnl_location_country  =
| addnl_location_city2    =
| addnl_location_country2 =
| coordinates             =
| origins                 =
| region_served           = <!-- or |area_served = or |region = -->
| products                = <!-- or |product = -->
| services                =
| methods                 = <!-- or |method = -->
| fields                  = [[Molecular biology|Basic molecular biology research]],<br />[[Clinical research]],<br />[[Systems medicine]],<br />Research on [[cardiovascular disease]]
| membership              = <!-- number of members -->
| membership_year         = <!-- year to which membership numbers/data apply -->
| language                = <!-- or |languages = --><!-- any official language or languages used -->
| owner                   = <!-- or |owners = -->
| sec_gen                 = <!-- or |gen_sec for General Secretary -->
| leader_title            = Scientific Director
| leader_name             = [[Maike Sander]]
| leader_title2           =
| leader_name2            =
| leader_title3           =
| leader_name3            =
| leader_title4           =
| leader_name4            =
| leader_title5           =
| leader_name5            =
| board_of_directors      =
| key_people              =
| main_organ              = <!-- or |publication = --><!-- organization's principal body (assembly, committee, board, etc.) or publication -->
| parent_organization     = [[Helmholtz Association]]
| subsidiaries            =
| secessions              =
| affiliations            =
| ror_id                  = <!-- unique ID in the Research Organization Registry -->
| budget                  =
| budget_year             =
| revenue                 =
| revenue_year            =
| disbursements           =
| expenses                =
| expenses_year           =
| endowment               =
| endowment_year          =
| funding                 = <!-- source of funding e.g. for "think tanks" -->
| staff                   = 1600<ref>{{cite web|access-date=2023-11-01|language=de|title=Helmholtz-Gemeinschaft deutscher Forschungszentren (HGF)|url=https://www.berlin.de/sen/wissenschaft/einrichtungen/forschungseinrichtungen/helmholtz-gemeinschaft/artikel.151455.php#mdc|website=berlin.de|date=15 September 2021 }}<!-- auto-translated by Module:CS1 translator --></ref>
| staff_year              = 2023
| volunteers              =
| volunteers_year         =
| students                =
| students_year           =
| awards                  =
| website                 = {{URL|mdc-berlin.de}}
| remarks                 =
| formerly                = <!-- or |former_name = -->
| footnotes               =
| bodystyle               =
}}
The '''Max Delbrück Center for Molecular Medicine in the Helmholtz Association''' ('''Max Delbrück Center''') in [[Berlin]] is one of the 18 institutions that make up the [[Helmholtz Association]]. It combines [[Molecular biology|basic molecular biology research]] with [[clinical research]] and is dedicated to the research foci of [[systems medicine]] and [[cardiovascular disease]]s. The research center is named after the Berlin-born [[Biophysics|biophysicist]] and [[List of Nobel laureates|Nobel laureate]] [[Max Delbrück]]. The center is headed by Maike Sander.
== History ==
The Max Delbrück Center was established in [[Buch (Berlin)|Berlin-Buch]] in January 1992. [[Detlev Ganten]] was the founding director. The research center is the successor to three institutions that had belonged to the [[German Academy of Sciences at Berlin|Academy of Sciences of the GDR]] until 1990: the Central Institute for Molecular Biology (''Zentralinstitut für Molekularbiologie''), the Central Institute for Cancer Research (''Zentralinstitut für Krebsforschung''), and the Central Institute for Cardiovascular Research (''Zentralinstitut für Herz-Kreislaufforschung''), which had emerged from the Institute for Medicine and Biology (Institut für Medizin und Biologie) that had existed in Berlin-Buch since 1947.<ref>Heinz Bielka: ''Die Medizinisch-Biologischen Institute Berlin-Buch. Beiträge zur Geschichte. Mit 91 Abbildungen und zahlreichen Faksimile''. Springer. Berlin, Heidelberg, Singapur etc. 1997, p. 54–114, {{ISBN|978-3-540-62965-8}}.</ref>
In 1995, the research center became a member of the Helmholtz Association and in 2007 began operating a joint research center with [[Charité]]: the "Experimental and Clinical Research Center" (ECRC).<ref>''Kliniken in Berlin. Das älteste Krankenhaus der Stadt. Am Anfang war die Charité ein Pesthaus. Heute ist sie die größte Universitätsklinik Europas''. In: [[Berliner Zeitung]], 6 August 2008.</ref> In 2008, the "Berlin Institute for Medical Systems Biology" (MDC-BIMSB) opened, moving to its present home in [[Mitte (locality)|Berlin-Mitte]] in 2019.<ref name="BIMSB">{{cite web|access-date=2023-10-29|date=2019-02-26|language=DE|title=250 Forscher suchen in Mitte das Geheimnis des Lebens|url=https://www.bz-berlin.de/archiv-artikel/250-forscher-suchen-in-mitte-das-geheimnis-des-lebens|website=[[B.Z. (newspaper)|B.Z.]]}}<!-- auto-translated by Module:CS1 translator --></ref>
In 2013, the Max Delbrück Center was one of the founding members of the EU-LIFE Alliance, a network of European life sciences research centers promoting cutting-edge research.<ref>{{cite journal|author=Philip Hunter|date=2013-12-01|title=EU-LIFE revives funding debate|journal=EMBO Reports |volume=14 |issue=12 |pages=1047–1049 |doi=10.1038/embor.2013.183 |pmid=24232183 |pmc=3981084 }}<!-- auto-translated by Module:CS1 translator --></ref> In the same year, the Berlin Institute of Health at Charité (BIH) began operations, a joint endeavor of Charité and the Max Delbrück Center focused on [[translational medicine]] and [[personalized medicine|precision medicine]].<ref>{{cite news|access-date=2023-11-01|date=2013-06-19|language=de|title=Institut für Gesundheitsforschung eröffnet|url=https://taz.de/!477716/|website=[[Die Tageszeitung]]|page=22 }}<!-- auto-translated by Module:CS1 translator --></ref>
In 2021, BIH was integrated into the translational research area at Charité, forming its third pillar alongside the Clinical Center and the Medical Faculty; since then, the Max Delbrück Center has been a privileged partner of BIH.<ref>{{cite web|access-date=2023-11-01|author=Tilmann Warnecke|date=2019-04-05|language=de|title=Berliner Institut für Gesundheitsforschung: Das BIG wird in die Charité integriert|url=https://www.tagesspiegel.de/wissen/das-big-wird-in-die-charite-integriert-5937043.html|website=[[Der Tagesspiegel|Tagesspiegel]]}}<!-- auto-translated by Module:CS1 translator --></ref> In 2020, the Max Delbrück Center was one of the founders of BR50, an association of non-university research institutions that aims to strengthen the Berlin-Brandenburg region as a hub for science.<ref>{{cite web|access-date=2023-10-31|language=de|publisher=Forschungsverbund Berlin e.V.|title=Was ist BR50?|url=https://www.br50.org/br50/was-ist-br50|website=br50.org}}<!-- auto-translated by Module:CS1 translator --></ref><ref name="Köpfe">Torsten Harmsen: ''Kampf um die besten Köpfe''. In: ''Berliner Zeitung'', 6 Oktober 2021.</ref> The Max Delbrück Center and [[Heidelberg University]] founded the Helmholtz Institute for Translational AngioCardioScience (HI-TAC) in the summer of 2023 to conduct research on an early warning system for cardiovascular diseases.<ref>{{cite web|access-date=2023-10-31|author=Martin Ballaschk|date=2023-06-21|language=de|title=Nachhaltige Energien und Herz-Kreislauf-Forschung: Berliner Helmholtz-Zentren gründen zwei neue Institute|url=https://www.tagesspiegel.de/wissen/nachhaltige-energien-und-herz-kreislauf-forschung-berliner-helmholtz-zentren-grunden-zwei-neue-institute-10020079.html|website=Tagesspiegel}}<!-- auto-translated by Module:CS1 translator --></ref><ref>{{cite web|access-date=2023-10-31|author=Torsten Harmsen|date=2023-06-21|language=de|title=Wie Herz und Gefäße bestimmen, ob wir gesund bleiben oder krank werden|url=https://www.berliner-zeitung.de/mensch-metropole/berlin-gesundheit-neues-helmholtz-institut-wie-herz-und-gefaesse-bestimmen-ob-wir-gesund-bleiben-oder-krank-werden-li.361460|website=Berliner Zeitung}}<!-- auto-translated by Module:CS1 translator --></ref>
From 1992 to 2013, the Research Center awarded the [[Max Delbrück Medal]] annually as part of the Berlin Lectures on Molecular Medicine.
== Research program ==
The goal of research at the Max Delbrück Center is to investigate the causes of [[disease]] and [[health]] down to the smallest and most basic level and to put the knowledge gained and technological innovations developed into application as quickly as possible. The center’s research can be broken down into the following broad topics:<ref>{{cite web|access-date=2023-10-29|title=Research Program|url=https://www.mdc-berlin.de/research/discovery/program|website=mdc-berlin.de}}<!-- auto-translated by Module:CS1 translator --></ref>
* Genes, Cells and Cell‑based Medicine
* Molecular Processes and Therapies
* Integrative Biomedicine
The fourth focus, called "Cross-Cutting Areas," deals with<ref>{{cite web|access-date=2023-11-01|title=Cross-Cutting Areas|url=https://www.mdc-berlin.de/research/discovery/program/cross-cutting|website=mdc-berlin.de}}<!-- auto-translated by Module:CS1 translator --></ref>
* [[Data science|Data Science]] and [[Artificial intelligence|Artificial Intelligence]]
* [[Immunology]] and [[Inflammation]]
* Single cell approaches for personalized medicine
* Translational Vascular Biomedicine ("Berlin Center for Translational Vascular Biomedicine")
A special focus of the Max Delbrück Center is [[systems biology]], for which it founded the "Berlin Institute for Medical Systems Biology" (MDC-BIMSB) in 2008.
== Technology platforms ==
The Max Delbrück Center's scientific infrastructure includes 19 technology platforms (as of 2022).<ref>{{cite web|access-date=2023-10-24|date=2022-12-06|language=de|title=Im Portrait: Max Delbrück Center – Forschung mit dem Blick auf die kleinen wichtigen Dinge|url=https://www.healthcapital.de/news/artikel/max-delbrueck-center-forschung-mit-dem-blick-auf-die-kleinen-wichtigen-dinge/|website=healthcapital.de}}<!-- auto-translated by Module:CS1 translator --></ref> They support and develop established and standardized technologies as well as those that are still being explored, developed or researched.<ref>{{cite web|access-date=2023-10-24|language=de|publisher=[[Federal Office of Administration]]|title=Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC)|url=https://www.service.bund.de/Content/DE/DEBehoerden/H/Helmholtz-Gemeinschaft/MDC/Max-Delbrueck-Centrum-fuer-Molekulare-Medizin-Berlin-Buch.html|website=service.bund.de}}<!-- auto-translated by Module:CS1 translator --></ref>
== Collaborations ==
The Max Delbrück Center participates in multiple domestic and international research networks.<ref>See for example project EASI-Genomics {{cite web|access-date=2023-10-30|title=About|url=https://www.easi-genomics.eu/about#consortium|website=easi-genomics.eu}}<!-- auto-translated by Module:CS1 translator --></ref> Within Germany, collaboration with Charité is particarly close. The ECRC and the BIH are the institutions at the core of this collaborative partnership. The goal of the ECRC's work is to translate basic scientific findings into clinical applications in order to improve the [[diagnosis]], [[Preventive healthcare|prevention]], and [[therapy]] of common diseases (cardiovascular and [[Metabolic disorder|metabolic diseases]], [[cancer]], [[Neurological disorder|neurological diseases]]).<ref>{{cite web|access-date=2023-11-01|publisher=Campus Berlin-Buch GmbH|title=Experimental and Clinical Research Center (ECRC)|url=https://berlin-buch.com/de/clinical_research|website=berlin-buch.com}}<!-- auto-translated by Module:CS1 translator --></ref>
The Max Delbrück Center also collaborates with the other centers of the Helmholtz Association in the research field of "Helmholtz Health". Specifically, these are the [[German Cancer Research Center]], the [[German Center for Neurodegenerative Diseases]], the [[Helmholtz-Zentrum Dresden-Rossendorf]], the [[Helmholtz Centre for Infection Research]] and [[Helmholtz Zentrum München]]. Together with the [[Leibniz Association]], German universities, university hospitals, federal and state institutes, and the [[Fraunhofer Society]], a nationwide long-term health study has also been conducted since 2014 – the NAKO Health Study.<ref>{{cite web|access-date=2023-10-24|title=Helmholtz Health|url=https://www.helmholtz.de/en/research/research-fields/health/|website=helmholtz.de}}<!-- auto-translated by Module:CS1 translator --></ref>
In addition to individual studies in which the Max Delbrück Center cooperates with third parties, the center is also involved in comprehensive national research collaborations, such as the National Center for Tumor Diseases (''Nationales Centrum für Tumorerkrankungen'')<ref>{{cite web|access-date=2023-10-20|date=2023-02-04|language=DE|title=Berlin ist neuer Standort des Nationalen Centrums für Tumorerkrankungen|url=https://www.management-krankenhaus.de/news/berlin-ist-neuer-standort-des-nationalen-centrums-fuer-tumorerkrankungen|website=Management & Krankenhaus}}<!-- auto-translated by Module:CS1 translator --></ref> or the German Center for Cardiovascular Research (''Deutsches Zentrum für Herz-Kreislauf-Forschung'') as part of the "National Decade against Cancer".<ref>{{cite web|access-date=2023-10-30|publisher=Deutsches Zentrum für Herz-Kreislauf-Forschung e. V.|title=Mitgliedseinrichtungen|url=https://dzhk.de/das-dzhk/ueber-uns/mitgliedseinrichtungen/|website=dzhk.de}}<!-- auto-translated by Module:CS1 translator --></ref>
The Max Delbrück Center is also involved in major international research collaborations, such as participating in the creation of the “Heart Atlas”, a sub-project of the [[Human Cell Atlas]].<ref>Sabine Sütterlin: ''Pfadfinder für die Gesundheit''. In: ''Berliner Zeitung'', 4 November 2020.</ref> It also drove the creation of the "Fly Cell Atlas,"<ref>{{cite journal|access-date=2023-10-15|date=2022-03-04|language=EN|title=Fly Cell Atlas: A single-nucleus transcriptomic atlas of the adult fruit fly|url=https://www.science.org/doi/10.1126/science.abk2432|journal=[[Science (journal)|Science]]|doi=10.1126/science.abk2432 |last1=Li |first1=Hongjie |last2=Janssens |first2=Jasper |last3=De Waegeneer |first3=Maxime |last4=Kolluru |first4=Sai Saroja |last5=Davie |first5=Kristofer |last6=Gardeux |first6=Vincent |last7=Saelens |first7=Wouter |last8=David |first8=Fabrice P. A. |last9=Brbić |first9=Maria |last10=Spanier |first10=Katina |last11=Leskovec |first11=Jure |last12=McLaughlin |first12=Colleen N. |last13=Xie |first13=Qijing |last14=Jones |first14=Robert C. |last15=Brueckner |first15=Katja |last16=Shim |first16=Jiwon |last17=Tattikota |first17=Sudhir Gopal |last18=Schnorrer |first18=Frank |last19=Rust |first19=Katja |last20=Nystul |first20=Todd G. |last21=Carvalho-Santos |first21=Zita |last22=Ribeiro |first22=Carlos |last23=Pal |first23=Soumitra |last24=Mahadevaraju |first24=Sharvani |last25=Przytycka |first25=Teresa M. |last26=Allen |first26=Aaron M. |last27=Goodwin |first27=Stephen F. |last28=Berry |first28=Cameron W. |last29=Fuller |first29=Margaret T. |last30=White-Cooper |first30=Helen |volume=375 |issue=6584 |pmid=35239393 |display-authors=1 |hdl=10261/306874 |hdl-access=free }}<!-- auto-translated by Module:CS1 translator --></ref> as well as research on chronic diseases with high morbidity and mortality (e.g., cardiometabolic or [[neurodegenerative diseases]]) and cancer in the "NOVA Institute for Medical Systems Biology" (NIMSB) in [[Portugal]].<ref>{{cite web|access-date=2023-11-01|date=2023-10-24|language=EN|title=Official launch of NIMSB - NOVA Institute for Medical Systems Biology: towards a holistic view of health|url=https://www.unl.pt/en/news/nova/official-launch-nimsb-nova-institute-medical-systems-biology-towards-holistic-view-health|website=Website of [[Universidade Nova de Lisboa]]}}<!-- auto-translated by Module:CS1 translator --></ref><ref>{{cite web|access-date=2023-10-30|title=NOVA Institute for Medical Systems Biology|url=https://cordis.europa.eu/project/id/101060346/de|website=cordis.europa.eu}}<!-- auto-translated by Module:CS1 translator --></ref>
== Spin-offs and public engagement ==
Six companies were founded out of the Max Delbrück Center between 1997 and 2021. These [[Corporate spin-off|spin-offs]] are dedicated to researching therapies for serious illnesses such as cancer and muscle diseases.<ref>1997: EPO Experimentelle Pharmakologie & Onkologie Berlin-Buch GmbH, new registration in the [[German Commercial Register]] (12 March 1997). 2010: MRI.TOOLS GmbH,  new registration in the German Commercial Register (15 October 2010). 2013: OMEICOS Therapeutics GmbH, new registration in the German Commercial Register (9 July 2013). 2014: Berlin Cures Holding AG. See Marco Mrusek: ''Nebulöses um Long-COVID''. In: [[Ärzte Zeitung]], Issue 56/2022. 2015: T-Knife GmbH. See Maike Telgheder: ''Die Biontechs von morgen''. In: [[Handelsblatt]], 17 September 2021. 2021: MyoPax GmbH, new registration in the German Commercial Register (15 September 2021)</ref> In terms of public engagement, the Max Delbrück Center participates in [[outreach]] activities such as the Berlin Science Week, the annual Long Night of Science in Berlin and the Life Science Learning Lab to inform, engage, and interest the general public in its research and work.<ref>See for instance Norman Börner: ''Lange Nacht der Wissenschaften: Forschung mit Spaßfaktor''. In: ''Berliner Morgenpost'', 18 June 2023. In addition {{cite web|access-date=2023-11-01|date=2022-10-31|publisher=Forschungsverbund Berlin e.V.|title=FVB@BerlinScienceWeek 2022|url=https://www.fv-berlin.de/infos-fuer/medien-und-oeffentlichkeit/news/fvbberlinscienceweek-2022}}<!-- auto-translated by Module:CS1 translator --> See also Thomas Oberländer: ''Medizin Pur''. In: ''Berliner Zeitung'', 7 June 2016.</ref><ref>{{cite web|access-date=2023-10-30|publisher=Campus Berlin-Buch GmbH|title=Education and Knowledge Transfer|url=https://www.campusberlinbuch.de/en/wissensvermittlung|website=campusberlinbuch.de}}<!-- auto-translated by Module:CS1 translator --></ref>
== Funding and management ==
The Max Delbrück Center receives 90% of its funding from the Federal Government of Germany and 10% from the State of Berlin, in addition to third-party funding. Total basic funding for 2022 was 105.5 million euros; total third-party funding and other income was 36.6 million euros<ref>{{cite web|access-date=2023-11-01|title=Facts and figures|url=https://www.mdc-berlin.de/about/us/facts|website=mdc-berlin.de}}<!-- auto-translated by Module:CS1 translator --></ref>
Since November 1, 2022, Maike Sander has served as Scientific Director and Chairperson of the Board of Directors.<ref>{{cite web|access-date=2023-10-24|language=de|title=Maike Sander: An der Spitze des Max-Delbrück-Centrums|url=https://www.aerzteblatt.de/archiv/226369/Maike-Sander-An-der-Spitze-des-Max-Delbrueck-Centrums|website=[[Deutsches Ärzteblatt]]|date=8 August 2022 }}<!-- auto-translated by Module:CS1 translator --></ref>
== Animal experiments and alternatives ==
The research center is a member of the European Animal Research Association (EARA)<ref>{{cite web|access-date=2023-10-30|title=Our Members (EARA)|url=https://www.eara.eu/our-members|website=eara.eu}}<!-- auto-translated by Module:CS1 translator --></ref> and has signed the [[Basel Declaration]], which commits to the highest ethical standards in animal experimentation and calls for an open dialogue on the use of animals in research.<ref>Anne Rasmus: ''Der Multiorganchip soll die Maus ersetzen''. In: ''Berliner Zeitung'', 20 June 2016.</ref><ref>{{cite journal|access-date=2023-10-24|author=Alison Abbott|date=2010-12-06|title=Basel Declaration defends animal research|url=https://www.nature.com/articles/468742a|journal=[[Nature (journal)|Nature]]|volume=468 |issue=7325 |page=742 |doi=10.1038/468742a |pmid=21150964 }}<!-- auto-translated by Module:CS1 translator --></ref>
In 2021, the Max Delbrück Center was awarded the "Transparent Animal Experiments" seal.<ref>{{cite web|access-date=2022-11-02|author=TVV|date=2021-04-13|language=de|title=Qualitätssiegel für Best Practice in der Tierversuchs-Kommunikation|url=https://www.tierversuche-verstehen.de/qualitaetssiegel-fuer-tierversuchs-kommunikation/|website=Tierversuche verstehen}}<!-- auto-translated by Module:CS1 translator --></ref> In the same year, the center joined with other research institutions to found the "Einstein Center 3R," an initiative to strengthen alternative methods in biomedical research and to add weight to [[animal welfare]].<ref>{{cite news|access-date=2023-06-28|date=2021-06-16|language=de|title=Reduktion von Tierversuchen|url=https://taz.de/!5775027/|newspaper=Die Tageszeitung: Taz|page=22 }}<!-- auto-translated by Module:CS1 translator --></ref>
==See also==
*[[Universities and research institutions in Berlin]]
==References==
{{reflist}}
==External links==
*{{Official website|https://www.mdc-berlin.de}}
{{coord|52|37|29.4|N|13|30|9.4|E|type:landmark_region:DE|display=title}}
{{Authority control}}
{{DEFAULTSORT:Max Delbruck Center for Molecular Medicine}}
[[Category:Genetics in Germany]]
[[Category:Medical research institutes in Germany]]
[[Category:Medical and health organisations based in Berlin]]
[[Category:Molecular biology institutes]]
[[Category:Research institutes established in 1992]]
[[Category:Research institutes in Berlin]]